Evidence map›Paper›PMID 30576664›Full record

ArticleAmerican journal of obstetrics and gynecology2019

Predictors of contraceptive switching and discontinuation within the first 6 months of use among Highly Effective Reversible Contraceptive Initiative Salt Lake study participants.

Rebecca G Simmons, Jessica N Sanders, Claudia Geist, Lori Gawron, Kyl Myers, David K Turok

2 registry-linked trialsAbstract read
In one paragraph

Article in American journal of obstetrics and gynecology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05695352 phase2completednot on this mapstarted 2022, after this paper: background citation

A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Normal Menstruating Women

TypeinterventionalSponsorInnovaGyn, Inc.Ran2022 to 2025Enrolled19ConditionsPregnancy PreventionArmsLevonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
NCT06306131 phase2completednot on this mapstarted 2023, after this paper: background citation

A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women

TypeinterventionalSponsorInnovaGyn, Inc.Ran2023 to 2025Enrolled4ConditionsPregnancy PreventionArmsLevonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rebecca G SimmonsDepartment of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT. Electronic address: rebecca.simmons@hsc.utah.edu.
Jessica N SandersDepartment of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT.
Claudia GeistDepartment of Sociology, University of Utah, Salt Lake City, UT.
Lori GawronDepartment of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT.
Kyl MyersDepartment of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT.
David K TurokDepartment of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT.
University of Utah · US

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
UNIVERSITY OF UTAH CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCE-UL1: BPCAUL1RR025764 · NCRR · UNIVERSITY OF UTAH · PI MCCLAIN, DONALD A. · 2008 to 2011
$19.4M
University of Utah Center for Clinical and Translational Science-UL1UL1TR000105 · NCATS · UNIVERSITY OF UTAH · PI MCCLAIN, DONALD A. · 2012 to 2013
$5.1M
Utah Women's Reproductive Health Research Career Development ProgramK12HD085816 · NICHD · UNIVERSITY OF UTAH · PI SILVER, ROBERT M. · 2015 to 2024
$3.2M
Utah Building Interdisciplinary Resreach Careers in Women's Health Career Development ProgramK12HD085852 · NICHD · UNIVERSITY OF UTAH · PI VARNER, MICHAEL W. · 2015 to 2019
$2.3M
Midcareer Investigator Award in Patient-Oriented Research K24K24HD087436 · NICHD · UNIVERSITY OF UTAH · PI TUROK, DAVID · 2017 to 2021
$942k
NCATS NIH HHS UL1 TR000105NCATS NIH HHS UL1 TR002538NCRR NIH HHS UL1 RR025764NICHD NIH HHS K12 HD085816NICHD NIH HHS K12 HD085852NICHD NIH HHS K24 HD087436
6 · The paper itself

Abstract

backgroundNearly half of women will switch or discontinue using their selected contraceptive method in the first year. Research on early switching or discontinuation provides important clinical and public health insights, although few studies have assessed associated factors, particularly among longitudinal cohorts.

objectiveThe current study explores attributes associated with early contraceptive method switching or discontinuation (<6 months of initiation) among participants enrolled in the intervention cohorts of the Highly Effective Reversible Contraceptive Initiative Salt Lake Contraceptive Initiative (Utah, United States). MATERIALS AND

methodsHighly Effective Reversible Contraceptive Initiative Salt Lake participants have access to no-cost contraception for 3 years. This includes both the initial selection and the ability to switch or to discontinue methods without cost. Methods available included the following: nonhormonal behavioral methods (male/female condoms, withdrawal, diaphragms, cervical caps, and fertility awareness); short-acting methods (pill, patch, ring, and injectable); and long-acting methods (intrauterine devices and contraceptive implants). Participants completed surveys at baseline and at 1, 3, and 6 months. We collected data on participant demographics, contraceptive continuation, switching, and discontinuation, as well as factors associated with these changes, including established measures of pregnancy intention and ambivalence and reasons for switching or discontinuing. We conducted descriptive statistics, univariable, and multivariable Poisson regression analyses to assess predictors of both discontinuation and switching. We also conducted χ

resultsAt 6 months, 2,583 women (70.0%) reported continuation of their baseline method, 367 (10%) reported at least 1 period of discontinuation, 459 (12.4%) reported switching to a different method, and 279 (7.6%) did not provide 6-month follow-up. Factors associated with discontinuation included selection of a short-acting method (incidence rate ratio [IRR], 2.49; 95% confidence interval [CI], 1.97, 3.12), report of Hispanic ethnicity (IRR, 1.45; 95% CI, 1.12, 1.89) and nonwhite race (IRR, 1.48; 95% CI, 1.08, 2.02), and having any future pregnancy plans, even years out. Participants with some college education were less likely to report discontinuation (IRR, 0.73; 95% CI, 0.57, 0.94). Selecting a short-acting method at baseline was also associated with increased likelihood of method switching (IRR, 2.29, 95% CI, 1.87, 2.80), as was having 2 or more children (IRR, 1.37; 95% CI, 1.08, 1.74). Women were less likely to switch if they were on their parents' insurance (IRR, 0.74; 95% CI, 0.56, 0.99). Among participants who switched methods, 36.9% switched to a long-acting reversible method, 31.7% switched to a short-acting hormonal method, and 31.1% switched to a nonhormonal behavioral method, such as condom use. Of participants providing a reason for stopping, 454 women (73.2%) reported side effects as 1 reason for switching or discontinuing their initial method.

conclusionEarly contraceptive method switching and discontinuation are frequent outcomes of contraceptive use. These changes are common even with removal of contraceptive access barriers.

Indexed as

Contraception BehaviorAdolescentAdultBlack or African AmericanCoitus InterruptusCondomsContraceptionContraceptives, Oral, HormonalEducational StatusFemaleHispanic or LatinoHumansIntentionLong-Acting Reversible ContraceptionMotivationNatural Family Planning MethodsContraceptives, Oral, Hormonalcontraceptiondiscontinuationfamily planningswitchingUnited States

Identifiers

PMID30576664
PMCPMC6861011
OpenAlexW2904393686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.